Medical Aspects of Chemical Warfare (2008) - The Black Vault

More documents

Recommendations

Info

Nerve Agents38. Grob D, Lilienthal JL Jr, Harvey AM, Jones BF. The administration of di-isopropyl fluorophosphate (DFP) to man, I:Effect on plasma and erythrocyte cholinesterase; general systemic effects; use in study of hepatic function and erythropoieses;and some properties of plasma cholinesterase. Bull Johns Hopkins Hosp. 1947;81:217–244.39. Rider JA, Moeller HC, Puletti EJ, Swader JI. Toxicity of parathion, systox, octamethyl pyrophosphoramide, and methylparathion in man. Toxicol Appl Pharmacol. 1969;14:603–611.40. Hayes GR Jr, Funckes AJ, Hartwell WV. Dermal exposure of human volunteers to parathion. Arch Environ Health.1964;8:829–833.41. Edson EF. No-effect levels of three organophosphates in the rat, pig, and man. Food Cosmet Toxicol. 1964;2:311–316.42. Rider JA, Puletti EJ, Swader JI. The minimal oral toxicity level for mevinphos in man. Toxicol Appl Pharmacol. 1975;32:97–100.43. Sidell FR, Groff WA. The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol Appl Pharmacol.1974;27:241–252.44. Sim VM. Variability of Different Intact Human Skin Sites to the Penetration of VX. Edgewood Arsenal, Md: Medical ResearchLaboratory; 1962. Chemical Research and Development Laboratory Report 3122.45. Grob D, Harvey JC. Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate).J Clin Invest. 1958;37:350–368.46. Grob D, Harvey AM. The effects and treatment of nerve gas poisoning. Am J Med. 1953;14:52–63.47. Sim VM, Stubbs JL. VX Percutaneous Studies in Man. Edgewood Arsenal, Md: Medical Research Laboratory; 1960.Chemical Research and Development Laboratory Report 3015.48. Craig FN, Cummings EG, Sim VM. Environmental temperature and the percutaneous absorption of a cholinesteraseinhibitor, VX. J Invest Dermatol. 1977;68:357–361.49. United Kingdom Ministry of Defence. Cholinesterase as an Aid in the Early Diagnosis of Nerve Gas Poisoning. Part II: TheVariation of Blood Cholinesterase in Man Before and After the Administration of Very Small Quantities of G Vapor by Inhalation.London, England: Ministry of Defence. Unpublished report.50. Harvey JC. Clinical Observations on Volunteers Exposed to Concentrations of GB. Edgewood Arsenal, Md: Medical ResearchLaboratory; 1952. Medical Laboratory Research Report 144.51. Craig AB, Woodson GS. Observations on the effects of exposure to nerve gas. I. Clinical observations and cholinesterasedepression. Am J Med Sci. 1959;238:13–17.52. Sidell RF. Clinical considerations in nerve agent intoxication. In: Somani SM, ed. Chemical Warfare Agents. San Diego,Calif: Academic Press; 1992: 163.53. Nohara M, Segawa K. Ocular symptoms due to organophosphorus gas (Sarin) poisoning in Matsumoto. Br J Ophthalmol.1996;80:1023.54. Namba T, Nolte CT, Jackrel J, Grob D. Poisoning due to organophosphate insecticides. Am J Med. 1971;50:475–492.55. Rengstorff RH. Accidental exposure to sarin: vision effects. Arch Toxicol. 1985;56:201–203.56. Johns RJ. The Effects of Low Concentrations of GB on the Human Eye. Edgewood Arsenal, Md: Medical Research Laboratory;1952. Medical Laboratory Research Report 100.57. Stewart WC, Madill HD, Dyer AM. Night vision in the miotic eye. Can Med Assoc J. 1968;99:1145–1148.207
Medical Aspects of Chemical Warfare58. Craig AB Jr, Freeman G. Clinical Observations on Workers Accidentally Exposed to “G” Agents. Edgewood Arsenal, Md:Medical Research Laboratory; 1953. Medical Laboratory Research Report 154.59. Rubin LS, Krop S, Goldberg MN. Effect of sarin on dark adaptation in man: mechanism of action. J Appl Physiol.1957;11:445–449.60. Rubin LS, Goldberg MN. Effect of tertiary and quaternary atropine salts on absolute scotopic threshold changes producedby an anticholinesterase (sarin). J Appl Physiol. 1958;12:305–310.61. Trusov MS. The effect of eserine upon light sensitivity and dark adaptation of the eye [in Russian]. Oftalmol Zh.1962;17:366–371.62. Moylan-Jones RJ, Thomas DP. Cyclopentolate in treatment of sarin miosis. Br J Pharmacol. 1973;48:309–313.63. United Kingdom Ministry of Defence. An evaluation of the functional changes produced by the inhalation of GBvapour. London, England: Ministry of Defence. Unpublished report.64. United Kingdom Ministry of Defence. Air-way Resistance Changes in Men Exposed to GB Vapour. London, England:Ministry of Defence. Unpublished report.65. Clements JA, Moore JC, Johnson RP, Lynott J. Observations on Airway Resistance in Men Given Low Doses of GB by ChamberExposure. Edgewood Arsenal, Md: Medical Research Laboratory; 1952. Medical Laboratory Research Report 122.66. Ward JR. Case report: Exposure to a nerve gas. In: Whittenberger JL, ed. Artificial Respiration: Theory and Applications.New York, NY: Harper & Row; 1962: 258–265.67. De Candole CA, Douglas WW, Evans CL, et al. The failure of respiration in death by anticholinesterase poisoning. BrJ Pharmacol Chemother. 1953;8:466–475.68. United Kingdom Ministry of Defence. The Predominantly Peripheral Effects of Acute GB Poisoning in Anaesthetized Animals.London, England: Ministry of Defence. Unpublished report.69. Johnson RP, Gold AJ, Freeman G. Comparative lung-airway resistance and cardiovascular effects in dogs and monkeysfollowing parathion and sarin intoxication. Am J Physiol. 1958;192:581–584.70. Fredriksson T, Hansson C, Holmstedt B. Effects of sarin in the anaesthetized and unanaesthetized dog followinginhalation. Percutaneous absorption and intravenous infusion. Arch Int Pharmacodyn Ther. 1960;126:288–302.71. Wright PG. An analysis of the central and peripheral components of respiratory failure produced by anticholinesterasepoisoning in the rabbit. J Physiol. 1954;126:52–70.72. Rickett DL, Glenn JF, Beers ET. Central respiratory effects versus neuromuscular actions of nerve agents. Neurotoxicology.1986;7:225–236.73. Kluwe WM, Chinn JC, Feder P, Olson C, Joiner R. Efficacy of pyridostigmine pretreatment against acute soman intoxicationin a primate model. In: Proceedings of the Sixth Medical Chemical Defense Bioscience Review. Aberdeen ProvingGround, Md: US Army Medical Research Institute for Chemical Defense; 1987: 227–234. Report AD B121516.74. Firemark H, Barlow CF, Roth LJ. The penetration of 2-PAM-C14 into brain and the effect of cholinesterase inhibitorson its transport. J Pharmacol Exp Ther. 1964;145:252–265.75. Lipp JA. Cerebral electrical activity following soman administration. Arch Int Pharmacodyn Ther. 1968;175:161–169.76. Carpentier P, Delamanche IS, LeBert M, Blanchet G, Bouchaud C. Seizure-related opening of the blood-brain barrierinduced by soman: possible correlation with the acute neuropathology observed in poisoned rats. Neurotoxicology.1990;11:493–508.208
Page 3 and 4:
The Coat of Arms1818Medical Departm
Page 5:
Textbooks of Military MedicinePubli
Page 8 and 9:
MEDICAL ASPECTS o fCHEMICAL WARFARE
Page 10 and 11:
ContentsContributorsForeword by The
Page 12 and 13:
ContributorsMICHAEL ADLER, PhDResea
Page 14 and 15:
DONALD M. MAXWELL, MSResearch Chemi
Page 16 and 17:
ForewordThe US military has been co
Page 18 and 19:
PrefaceA significant concern for th
Page 20:
PrologueThe original edition of Med
Page 23 and 24:
xxii
Page 25 and 26:
Medical Aspects of Chemical Warfare
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 178 and 179:
Nerve AgentsChapter 5NERVE AGENTSFR
Page 180 and 181: Nerve AgentsAbout 10,000 to 30,000
Page 182 and 183: Nerve Agentsphorofluoridate (DFP) w
Page 184 and 185: Nerve AgentsFig. 5-2. This schemati
Page 186 and 187: Nerve AgentsExhibit 5-1 continuedis
Page 188 and 189: Nerve Agentsactivity but only 15% t
Page 190 and 191: Nerve AgentsTABLE 5-3CHEMICAL, PHYS
Page 192 and 193: Nerve AgentsTABLE 5-4EFFECTS OF EXP
Page 194 and 195: Nerve Agentsaffecting the other eye
Page 196 and 197: Nerve Agentsmay cause severe rhinor
Page 198 and 199: Nerve Agentsof jerks and tremor.Cen
Page 200 and 201: Nerve Agentsand they were decreased
Page 202 and 203: Nerve Agentsnerve agent toxicity on
Page 204 and 205: Nerve Agentspatient. Decontaminatio
Page 206 and 207: Nerve AgentsFig. 5-5. The Mark I ki
Page 208 and 209: Nerve Agentsadministered intramuscu
Page 210 and 211: Nerve Agentsthat hydroxamine reacti
Page 212 and 213: Nerve AgentsOral administration may
Page 214 and 215: Nerve AgentsTABLE 5-7RECOMMENDED TH
Page 216 and 217: Nerve Agentsimpairment such as whee
Page 218 and 219: Nerve Agentssuboptimal, manner. The
Page 220 and 221: Nerve Agentsthan those who did not.
Page 222 and 223: Nerve Agentssible for binding nerve
Page 224 and 225: Nerve Agentsfor comparison was not
Page 226 and 227: Nerve AgentsTABLE 5-11EFFECTS OF PY
Page 228 and 229: Nerve Agentstivity of smooth muscle
Page 232 and 233: Nerve Agents77. McDonough JH, Shih
Page 234 and 235: Nerve Agents117. McLeod CG Jr, Sing
Page 236 and 237: Nerve Agents154. Tryphonas l, Veino
Page 238 and 239: Nerve Agents193. Funckes AJ. Treatm
Page 240 and 241: Nerve Agents235. Suzuki T, Morita H
Page 242: Nerve Agents274. Pellegrini JE, Bak
Page 245 and 246: Medical Aspects of Chemical Warfare
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
PROCESSMedical Aspects of Chemical
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Page 501 and 502:
Page 503 and 504:
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 534 and 535:
Triage of Chemical CasualtiesChapte
Page 536 and 537:
Triage of Chemical Casualtiesreceiv
Page 538 and 539:
Triage of Chemical Casualtiesentran
Page 540 and 541:
Triage of Chemical Casualtiescatego
Page 542 and 543:
Triage of Chemical CasualtiesIn a f
Page 544 and 545:
Triage of Chemical Casualtiesnose)
Page 546 and 547:
Triage of Chemical CasualtiesWith n
Page 548 and 549:
Triage of Chemical Casualties14. Sa
Page 550 and 551:
Decontamination of Chemical Casualt
Page 552 and 553:
Page 554 and 555:
Page 556 and 557:
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
Page 572 and 573:
Page 574 and 575:
Page 576 and 577:
Page 578 and 579:
Page 580:
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
Page 593 and 594:
Page 595 and 596:
Page 597 and 598:
Page 599 and 600:
Page 601 and 602:
Page 603 and 604:
Page 605 and 606:
Page 607 and 608:
Page 609 and 610:
Page 611 and 612:
Page 613 and 614:
Page 615 and 616:
Page 617 and 618:
Page 619 and 620:
Page 621 and 622:
Page 623 and 624:
Page 625 and 626:
Page 627 and 628:
Page 629 and 630:
Page 631 and 632:
Page 633 and 634:
Page 635 and 636:
Page 637 and 638:
Page 639 and 640:
Page 641 and 642:
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Page 649 and 650:
Page 651 and 652:
Page 653 and 654:
Page 655 and 656:
Page 657 and 658:
Page 659 and 660:
Page 661 and 662:
Page 663 and 664:
Page 665 and 666:
Page 667 and 668:
Page 669 and 670:
Page 671 and 672:
Page 673 and 674:
Page 675 and 676:
Page 677 and 678:
Page 679 and 680:
Page 681 and 682:
Page 683 and 684:
Page 685 and 686:
Page 687 and 688:
Page 689 and 690:
Page 691 and 692:
Page 693 and 694:
Page 695 and 696:
Page 697 and 698:
Page 699 and 700:
Page 701 and 702:
Page 703 and 704:
Page 705 and 706:
Page 707 and 708:
Page 709 and 710:
Page 711 and 712:
Page 713 and 714:
Page 715 and 716:
Page 717 and 718:
Page 719 and 720:
Page 721 and 722:
Page 723 and 724:
Page 725 and 726:
Page 727 and 728:
Page 729 and 730:
Page 731 and 732:
Page 733 and 734:
Page 735 and 736:
Page 737 and 738:
Page 739 and 740:
Page 741 and 742:
Page 743 and 744:
Page 745 and 746:
Page 747 and 748:
• Analyze using GC-MS with methan
Page 749 and 750:
Page 751 and 752:
Page 753 and 754:
Page 755 and 756:
Page 757 and 758:
Page 759 and 760:
Page 761 and 762:
Page 763 and 764:
Page 765 and 766:
Page 767 and 768:
Page 769 and 770:
Page 771 and 772:
Page 773 and 774:
Page 775 and 776:
Page 777 and 778:
Page 779 and 780:
Page 781 and 782:
Page 783 and 784:
Page 785 and 786:
Page 787 and 788:
Page 789 and 790:
Page 791 and 792:
Page 793 and 794:
Page 795 and 796:
Page 798 and 799:
Abbreviations and AcronymsAbBreviat
Page 800:
Abbreviations and AcronymsPADPRP: p
Page 803 and 804:
Page 805 and 806:
Page 807 and 808:
Page 809 and 810:
Page 811 and 812:
Page 813 and 814:
Page 815 and 816:
Page 817 and 818:
Page 819 and 820:
Page 821 and 822:
Page 823 and 824:
Page 825 and 826:
Page 827 and 828:
Page 829 and 830:
Page 831 and 832:
Page 833 and 834:
Page 835 and 836:
Page 837 and 838:
Page 839 and 840:
Page 841 and 842:
Page 843 and 844:
Page 845:
show all

Medical Aspects of Chemical Warfare (2008) - The Black Vault

Create successful ePaper yourself

Delete template?

Save as template?